JP7638215B2 - 腎障害の治療 - Google Patents

腎障害の治療 Download PDF

Info

Publication number
JP7638215B2
JP7638215B2 JP2021549211A JP2021549211A JP7638215B2 JP 7638215 B2 JP7638215 B2 JP 7638215B2 JP 2021549211 A JP2021549211 A JP 2021549211A JP 2021549211 A JP2021549211 A JP 2021549211A JP 7638215 B2 JP7638215 B2 JP 7638215B2
Authority
JP
Japan
Prior art keywords
renal
less
nucleotides
antibody
receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021549211A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022521591A (ja
JP2022521591A5 (enExample
Inventor
アレクサンダー クック，スチュアート
シェイファー，セバスチャン
アニンドヤ ウィドジャジャ，アニッサ
Original Assignee
シンガポール・ヘルス・サービシーズ・ピーティーイー・リミテッド
ナショナル ユニヴァーシティー オブ シンガポール
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by シンガポール・ヘルス・サービシーズ・ピーティーイー・リミテッド, ナショナル ユニヴァーシティー オブ シンガポール filed Critical シンガポール・ヘルス・サービシーズ・ピーティーイー・リミテッド
Publication of JP2022521591A publication Critical patent/JP2022521591A/ja
Publication of JP2022521591A5 publication Critical patent/JP2022521591A5/ja
Application granted granted Critical
Publication of JP7638215B2 publication Critical patent/JP7638215B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Endocrinology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2021549211A 2019-02-22 2020-02-21 腎障害の治療 Active JP7638215B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1902419.9 2019-02-22
GBGB1902419.9A GB201902419D0 (en) 2019-02-22 2019-02-22 Treatment of kidney injury
PCT/EP2020/054580 WO2020169783A1 (en) 2019-02-22 2020-02-21 Treatment of kidney injury

Publications (3)

Publication Number Publication Date
JP2022521591A JP2022521591A (ja) 2022-04-11
JP2022521591A5 JP2022521591A5 (enExample) 2023-02-14
JP7638215B2 true JP7638215B2 (ja) 2025-03-03

Family

ID=65998854

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021549211A Active JP7638215B2 (ja) 2019-02-22 2020-02-21 腎障害の治療

Country Status (15)

Country Link
US (3) US11339216B2 (enExample)
EP (1) EP3927742A1 (enExample)
JP (1) JP7638215B2 (enExample)
KR (1) KR20210144708A (enExample)
CN (1) CN113748131A (enExample)
AU (1) AU2020224346A1 (enExample)
BR (1) BR112021016613A2 (enExample)
CA (1) CA3130027A1 (enExample)
CL (1) CL2021002212A1 (enExample)
EA (1) EA202191988A1 (enExample)
GB (1) GB201902419D0 (enExample)
MX (1) MX2021010025A (enExample)
PH (1) PH12021552024A1 (enExample)
TW (1) TWI874359B (enExample)
WO (1) WO2020169783A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201902419D0 (en) 2019-02-22 2019-04-10 Singapore Health Serv Pte Ltd Treatment of kidney injury
TWI907583B (zh) * 2020-12-11 2025-12-11 大陸商江蘇恒瑞醫藥股份有限公司 Jak抑制劑在腎臟疾病中的應用
WO2023023473A1 (en) * 2021-08-16 2023-02-23 Sierra Oncology, Inc. Methods of using momelotinib to treat chronic kidney disease
CN115068442A (zh) * 2021-09-13 2022-09-20 荣灿生物医药技术(上海)有限公司 核酸的纳米颗粒组合物、其制备方法和用途
CN113960302B (zh) * 2021-09-29 2024-04-23 中国人民解放军军事科学院军事医学研究院 一种基于高内涵技术的肾毒性检测方法及其应用
US20230145258A1 (en) * 2021-11-11 2023-05-11 Laboratory Corporation Of America Holdings Predicting a Diagnostic Test Result From Patient Laboratory Testing History
US20250082608A1 (en) * 2021-12-16 2025-03-13 Singapore Health Services Pte Ltd. Treatment and prevention of glomerular disease
CN114982708A (zh) * 2022-05-11 2022-09-02 成都医学院第一附属医院 一种小鼠造影剂肾病模型及其构建方法
CN119233818A (zh) 2022-05-20 2024-12-31 学校法人藤田学园 用于肾损伤的治疗方法或预防方法中的药物组合物和包含该药物组合物的联用药、以及ccbl1抑制剂
GB202218388D0 (en) 2022-12-07 2023-01-18 Vvb Bio Pte Ltd GP130 antigen-binding molecules
CN120787238A (zh) 2023-01-06 2025-10-14 拉森医疗公司 用于治疗甲状腺眼病的抗IL-11Rα抗体
CN119925593B (zh) * 2023-06-05 2025-11-25 北京东方百泰生物科技股份有限公司 一种抗il-11单克隆抗体的药物制剂
GB202311050D0 (en) 2023-07-19 2023-08-30 Vvb Bio Pte Ltd GP130 antigen-binding molecules
GB202405551D0 (en) 2024-04-19 2024-06-05 Vvb Bio Pte Ltd Combination treatment
WO2025238135A2 (en) 2024-05-17 2025-11-20 UCB Biopharma SRL Antibody with binding specificity for il-11
GB202408044D0 (en) 2024-06-06 2024-07-24 Vvb Bio Pte Ltd gp130 antigen-binding molecules
CN119548507A (zh) * 2024-11-12 2025-03-04 安徽医科大学 5-甲基四氢叶酸在制备治疗肾脏纤维化的药物中的应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018187485A1 (en) 2017-04-04 2018-10-11 The George Washington University Combination therapy for treating cancer
JP2019502689A (ja) 2015-12-16 2019-01-31 シンガポール・ヘルス・サービシーズ・ピーティーイー・リミテッド 線維化の治療

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2259800T3 (es) 1990-06-11 2006-10-16 Gilead Sciences, Inc. Procedimientos de uso de ligandos de acido nucleico.
ES2093562B1 (es) 1995-05-26 1997-07-01 Univ Santiago Compostela Estabilizacion de sistemas coloidales mediante formacion de complejos ionicos lipido-polisacarido.
US6649192B2 (en) 1996-07-29 2003-11-18 Universidade De Santiago De Compostela Application of nanoparticles based on hydrophilic polymers as pharmaceutical forms
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
CA2237915A1 (en) 1998-05-19 1999-11-19 Stephen Shaughnessy Osteoporosis treatment
HK1047109A1 (zh) 1999-10-15 2003-02-07 University Of Massachusetts 作为指定基因干预工具的rna干预轨迹基因
MX352516B (es) 2006-07-05 2017-04-06 Fibrotech Therapeutics Pty Ltd Compuestos terapeuticos.
US8182814B2 (en) 2007-10-26 2012-05-22 Csl Limited Methods of treating inflammatory airway conditions by inhibition of IL-11 activity
JP5330398B2 (ja) 2007-10-26 2013-10-30 シーエスエル、リミテッド サイトカインムテイン
US8518888B2 (en) 2008-10-14 2013-08-27 Csl Limited Method of treatment of gastrointestinal-type cancer with antagonistic antibodies to IL-11R
CN117843785A (zh) 2013-02-07 2024-04-09 Csl有限公司 Il-11r结合蛋白及其应用
CN108210909A (zh) * 2016-12-15 2018-06-29 深圳瑞健生命科学研究院有限公司 预防和治疗脂质肾损伤的药物及其用途
CN108210894A (zh) * 2016-12-15 2018-06-29 深圳瑞健生命科学研究院有限公司 预防和治疗病理性肾组织损伤的药物及其用途
US20180186871A1 (en) * 2016-12-16 2018-07-05 Singapore Health Services Pte Ltd. Il-11 antibodies
GB201621431D0 (en) 2016-12-16 2017-02-01 Singapore Health Services Pte Ltd And Nat Univ Of Singapore The Decoy cytokine receptor
GB201621439D0 (en) 2016-12-16 2017-02-01 Singapore Health Services Pte Ltd And Nat Univ Of Singapore IL-11Ra Antibodies
GB201716733D0 (en) * 2017-10-12 2017-11-29 Nat Univ Singapore Treatment of SMC mediated disease
GB201806918D0 (en) 2018-04-27 2018-06-13 Enleofen Bio Pte Ltd Combination treatment for eye fibrosis
GB201809700D0 (en) 2018-06-13 2018-08-01 Singapore Health Serv Pte Ltd IL-11 antibodies
GB201809699D0 (en) 2018-06-13 2018-08-01 Singapore Health Serv Pte Ltd IL-11 antibodies
GB201902419D0 (en) 2019-02-22 2019-04-10 Singapore Health Serv Pte Ltd Treatment of kidney injury

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019502689A (ja) 2015-12-16 2019-01-31 シンガポール・ヘルス・サービシーズ・ピーティーイー・リミテッド 線維化の治療
WO2018187485A1 (en) 2017-04-04 2018-10-11 The George Washington University Combination therapy for treating cancer

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Am. J. Physiol. Renal Physiol.，2011年，301，F1334-F1345
PLoS ONE，2012年，7(10)，e47160 page 1-15，DOI:10.1371/journal.pone.0047160

Also Published As

Publication number Publication date
GB201902419D0 (en) 2019-04-10
AU2020224346A1 (en) 2021-10-07
US20250270310A1 (en) 2025-08-28
CA3130027A1 (en) 2020-08-27
US11339216B2 (en) 2022-05-24
JP2022521591A (ja) 2022-04-11
KR20210144708A (ko) 2021-11-30
CN113748131A (zh) 2021-12-03
BR112021016613A2 (pt) 2021-11-03
TWI874359B (zh) 2025-03-01
TW202037605A (zh) 2020-10-16
US12234284B2 (en) 2025-02-25
MX2021010025A (es) 2021-11-12
EP3927742A1 (en) 2021-12-29
EA202191988A1 (ru) 2021-12-08
US20200270340A1 (en) 2020-08-27
US20220403017A1 (en) 2022-12-22
PH12021552024A1 (en) 2022-08-22
TW202521575A (zh) 2025-06-01
CL2021002212A1 (es) 2022-04-18
WO2020169783A1 (en) 2020-08-27

Similar Documents

Publication Publication Date Title
JP7638215B2 (ja) 腎障害の治療
JP7595028B2 (ja) 代謝性疾患の治療および予防
JP7514846B2 (ja) 肝毒性の治療
US20240141004A1 (en) Treatment of smc mediated disease
JP2023547468A (ja) 健康寿命を延長し加齢性疾患を処置する方法
US20230212279A1 (en) Treatment and prevention of disease caused by type iv collagen dysfunction
TWI923323B (zh) 腎損傷之治療
EP4448096A1 (en) Treatment and prevention of glomerular disease
EA049726B1 (ru) Лечение поражения почек
JP2024526944A (ja) アルコール性肝疾患の処置および予防
EA047713B1 (ru) Лечение гепатотоксичности

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211104

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230206

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230206

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240206

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240502

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240723

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241015

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20250110

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250128

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250218

R150 Certificate of patent or registration of utility model

Ref document number: 7638215

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150